← Leaderboards
Supriya K Saha
Massachusetts General Hospital
$1,502,420
Attributed
$1,502,420
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $586.9K · FY2015–19$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,502,420 · 3
By mechanism
K08$865,620 · 1
R21$636,800 · 2
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Nabeel Bardeesy$18,920,034
- David B Sykes$998,320
- Sita Kugel$5,881,835
- Alejandro Soto-Gutierrez$6,883,976
- Nir Hacohen$29,379,938
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCell LineResponseScreeningMalignant Neoplasm Of LiverNovel TherapeuticsIncidenceResistanceMutantIn VitroPreventionMalignant NeoplasmsClinical TrialsMolecular ProfilingFutureCholangiocarcinomaMutationCombinatorialDesignInhibitor/AntagonistIntrahepatic CholangiocarcinomaIsocitrate DehydrogenaseMouse ModelInfiltration
Grant awards (9)
Evaluating Novel Targeted Therapies in Cholangiocarcinoma Using Tumor Slice Cultures$242,562
R21 · FY2019 · CA · contact PI
Exploring immune surveillance in isocitrate dehydrogenase mutant cholangiocarcinoma$175,268
R21 · FY2019 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinoma$169,020
K08 · FY2019 · CA · contact PI
Exploring immune surveillance in isocitrate dehydrogenase mutant cholangiocarcinoma$218,970
R21 · FY2018 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinoma$169,020
K08 · FY2018 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinoma$169,020
K08 · FY2017 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinoma$120,798
K08 · FY2016 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutant cholangiocarcinoma$58,482
K08 · FY2016 · CA · contact PI
Novel targeted therapies for isocitrate dehydrogenase mutant cholangiocarcinoma$179,280
K08 · FY2015 · CA · contact PI